J&J Revises Doxil Label To Include Cardiotoxicity Data For Liposomal Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
The risk of cardiotoxicity for liposomal doxorubicin is 11% based on a 250-patient breast cancer trial, updated labeling states. Labeling previously said that Doxil's myocardial toxicity would likely be similar to the risk of conventional formulations, which ranges from 6% to 20%.